CGRP Mechanism Antagonists and Migraine Management
Migraine is a complex disorder of the brain that is common and highly disabling. As understanding of the neural pathways has advanced, and it has become clear that the vascular hypothesis does not explain the disorder, new therapeutic avenues have arisen. One such target is calcitonin gene-related p...
Gespeichert in:
| Veröffentlicht in: | Current neurology and neuroscience reports 2015-05, Vol.15 (5), p.25-25 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 25 |
|---|---|
| container_issue | 5 |
| container_start_page | 25 |
| container_title | Current neurology and neuroscience reports |
| container_volume | 15 |
| creator | Karsan, Nazia Goadsby, Peter J. |
| description | Migraine is a complex disorder of the brain that is common and highly disabling. As understanding of the neural pathways has advanced, and it has become clear that the vascular hypothesis does not explain the disorder, new therapeutic avenues have arisen. One such target is calcitonin gene-related peptide (CGRP)-based mechanisms. CGRP is found within the trigeminovascular nociceptive system widely from the trigeminal ganglion to second-order and third-order neurons and in regulatory areas in the brainstem. Studies have shown CGRP is released during severe migraine attacks and the reversal of the attack with effective triptan treatment normalizes those levels. CGRP administration triggers migraine in patients, and CGRP receptor antagonists have been shown to abort migraine. Here, we review the current state of CGRP mechanism antagonist therapy as its research and development is increasing in migraine therapeutics. We discuss several recent trials, highlighting the evidence base behind these novel drugs, and their potential future contribution to migraine management. |
| doi_str_mv | 10.1007/s11910-015-0547-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1665123964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1665123964</sourcerecordid><originalsourceid>FETCH-LOGICAL-p254t-e87b601656bafe0d297a678aed1d886060bf84b33e3e3f93ddd4be087d50f2f33</originalsourceid><addsrcrecordid>eNo1kE1PwzAMQCMEYmPwA7igHrkEnM82x2mCgbQJhOAcpYtbOq3paLoD-_Vk2pAPtuRny36E3DJ4YAD5Y2TMMKDAFAUlc7o_I2OmhKSaG3F-qHlBJUg-IlcxrgF4mjKXZMRVbsAoNSZ8Nv94z5a4-nahiW02DYOru1QOMXPBZ8um7l0TMFu64GpsMQzX5KJym4g3pzwhX89Pn7MXunibv86mC7rlSg4Ui7zUwLTSpasQPDe503nh0DNfFBo0lFUhSyEwRWWE916WCEXuFVS8EmJC7o97t333s8M42LaJK9xsXMBuFy3TWjEujJYJvTuhu7JFb7d907r-1_7_mQB-BGJqhRp7u-52fUjnWwb2INMeZdok0x5k2r34A_PrY9Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1665123964</pqid></control><display><type>article</type><title>CGRP Mechanism Antagonists and Migraine Management</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Karsan, Nazia ; Goadsby, Peter J.</creator><creatorcontrib>Karsan, Nazia ; Goadsby, Peter J.</creatorcontrib><description>Migraine is a complex disorder of the brain that is common and highly disabling. As understanding of the neural pathways has advanced, and it has become clear that the vascular hypothesis does not explain the disorder, new therapeutic avenues have arisen. One such target is calcitonin gene-related peptide (CGRP)-based mechanisms. CGRP is found within the trigeminovascular nociceptive system widely from the trigeminal ganglion to second-order and third-order neurons and in regulatory areas in the brainstem. Studies have shown CGRP is released during severe migraine attacks and the reversal of the attack with effective triptan treatment normalizes those levels. CGRP administration triggers migraine in patients, and CGRP receptor antagonists have been shown to abort migraine. Here, we review the current state of CGRP mechanism antagonist therapy as its research and development is increasing in migraine therapeutics. We discuss several recent trials, highlighting the evidence base behind these novel drugs, and their potential future contribution to migraine management.</description><identifier>ISSN: 1528-4042</identifier><identifier>EISSN: 1534-6293</identifier><identifier>DOI: 10.1007/s11910-015-0547-z</identifier><identifier>PMID: 25790955</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Animals ; Calcitonin Gene-Related Peptide - antagonists & inhibitors ; Calcitonin Gene-Related Peptide - metabolism ; Disease Management ; Headache (RB Halker ; Humans ; Medicine ; Medicine & Public Health ; Migraine Disorders - drug therapy ; Migraine Disorders - pathology ; Nervous System - drug effects ; Nervous System - metabolism ; Neurology ; Neurosciences ; Receptors, Calcitonin Gene-Related Peptide - metabolism ; Section Editor ; Topical Collection on Headache</subject><ispartof>Current neurology and neuroscience reports, 2015-05, Vol.15 (5), p.25-25</ispartof><rights>Springer Science+Business Media New York 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-p254t-e87b601656bafe0d297a678aed1d886060bf84b33e3e3f93ddd4be087d50f2f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11910-015-0547-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11910-015-0547-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25790955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karsan, Nazia</creatorcontrib><creatorcontrib>Goadsby, Peter J.</creatorcontrib><title>CGRP Mechanism Antagonists and Migraine Management</title><title>Current neurology and neuroscience reports</title><addtitle>Curr Neurol Neurosci Rep</addtitle><addtitle>Curr Neurol Neurosci Rep</addtitle><description>Migraine is a complex disorder of the brain that is common and highly disabling. As understanding of the neural pathways has advanced, and it has become clear that the vascular hypothesis does not explain the disorder, new therapeutic avenues have arisen. One such target is calcitonin gene-related peptide (CGRP)-based mechanisms. CGRP is found within the trigeminovascular nociceptive system widely from the trigeminal ganglion to second-order and third-order neurons and in regulatory areas in the brainstem. Studies have shown CGRP is released during severe migraine attacks and the reversal of the attack with effective triptan treatment normalizes those levels. CGRP administration triggers migraine in patients, and CGRP receptor antagonists have been shown to abort migraine. Here, we review the current state of CGRP mechanism antagonist therapy as its research and development is increasing in migraine therapeutics. We discuss several recent trials, highlighting the evidence base behind these novel drugs, and their potential future contribution to migraine management.</description><subject>Animals</subject><subject>Calcitonin Gene-Related Peptide - antagonists & inhibitors</subject><subject>Calcitonin Gene-Related Peptide - metabolism</subject><subject>Disease Management</subject><subject>Headache (RB Halker</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Migraine Disorders - drug therapy</subject><subject>Migraine Disorders - pathology</subject><subject>Nervous System - drug effects</subject><subject>Nervous System - metabolism</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Receptors, Calcitonin Gene-Related Peptide - metabolism</subject><subject>Section Editor</subject><subject>Topical Collection on Headache</subject><issn>1528-4042</issn><issn>1534-6293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1PwzAMQCMEYmPwA7igHrkEnM82x2mCgbQJhOAcpYtbOq3paLoD-_Vk2pAPtuRny36E3DJ4YAD5Y2TMMKDAFAUlc7o_I2OmhKSaG3F-qHlBJUg-IlcxrgF4mjKXZMRVbsAoNSZ8Nv94z5a4-nahiW02DYOru1QOMXPBZ8um7l0TMFu64GpsMQzX5KJym4g3pzwhX89Pn7MXunibv86mC7rlSg4Ui7zUwLTSpasQPDe503nh0DNfFBo0lFUhSyEwRWWE916WCEXuFVS8EmJC7o97t333s8M42LaJK9xsXMBuFy3TWjEujJYJvTuhu7JFb7d907r-1_7_mQB-BGJqhRp7u-52fUjnWwb2INMeZdok0x5k2r34A_PrY9Q</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Karsan, Nazia</creator><creator>Goadsby, Peter J.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20150501</creationdate><title>CGRP Mechanism Antagonists and Migraine Management</title><author>Karsan, Nazia ; Goadsby, Peter J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p254t-e87b601656bafe0d297a678aed1d886060bf84b33e3e3f93ddd4be087d50f2f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Calcitonin Gene-Related Peptide - antagonists & inhibitors</topic><topic>Calcitonin Gene-Related Peptide - metabolism</topic><topic>Disease Management</topic><topic>Headache (RB Halker</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Migraine Disorders - drug therapy</topic><topic>Migraine Disorders - pathology</topic><topic>Nervous System - drug effects</topic><topic>Nervous System - metabolism</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Receptors, Calcitonin Gene-Related Peptide - metabolism</topic><topic>Section Editor</topic><topic>Topical Collection on Headache</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karsan, Nazia</creatorcontrib><creatorcontrib>Goadsby, Peter J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Current neurology and neuroscience reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karsan, Nazia</au><au>Goadsby, Peter J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CGRP Mechanism Antagonists and Migraine Management</atitle><jtitle>Current neurology and neuroscience reports</jtitle><stitle>Curr Neurol Neurosci Rep</stitle><addtitle>Curr Neurol Neurosci Rep</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>15</volume><issue>5</issue><spage>25</spage><epage>25</epage><pages>25-25</pages><issn>1528-4042</issn><eissn>1534-6293</eissn><abstract>Migraine is a complex disorder of the brain that is common and highly disabling. As understanding of the neural pathways has advanced, and it has become clear that the vascular hypothesis does not explain the disorder, new therapeutic avenues have arisen. One such target is calcitonin gene-related peptide (CGRP)-based mechanisms. CGRP is found within the trigeminovascular nociceptive system widely from the trigeminal ganglion to second-order and third-order neurons and in regulatory areas in the brainstem. Studies have shown CGRP is released during severe migraine attacks and the reversal of the attack with effective triptan treatment normalizes those levels. CGRP administration triggers migraine in patients, and CGRP receptor antagonists have been shown to abort migraine. Here, we review the current state of CGRP mechanism antagonist therapy as its research and development is increasing in migraine therapeutics. We discuss several recent trials, highlighting the evidence base behind these novel drugs, and their potential future contribution to migraine management.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>25790955</pmid><doi>10.1007/s11910-015-0547-z</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1528-4042 |
| ispartof | Current neurology and neuroscience reports, 2015-05, Vol.15 (5), p.25-25 |
| issn | 1528-4042 1534-6293 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1665123964 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Animals Calcitonin Gene-Related Peptide - antagonists & inhibitors Calcitonin Gene-Related Peptide - metabolism Disease Management Headache (RB Halker Humans Medicine Medicine & Public Health Migraine Disorders - drug therapy Migraine Disorders - pathology Nervous System - drug effects Nervous System - metabolism Neurology Neurosciences Receptors, Calcitonin Gene-Related Peptide - metabolism Section Editor Topical Collection on Headache |
| title | CGRP Mechanism Antagonists and Migraine Management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T16%3A16%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CGRP%20Mechanism%20Antagonists%20and%20Migraine%20Management&rft.jtitle=Current%20neurology%20and%20neuroscience%20reports&rft.au=Karsan,%20Nazia&rft.date=2015-05-01&rft.volume=15&rft.issue=5&rft.spage=25&rft.epage=25&rft.pages=25-25&rft.issn=1528-4042&rft.eissn=1534-6293&rft_id=info:doi/10.1007/s11910-015-0547-z&rft_dat=%3Cproquest_pubme%3E1665123964%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1665123964&rft_id=info:pmid/25790955&rfr_iscdi=true |